Clicky

iTeos Therapeutics, Inc.(ITOS)

Description: Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Adenosine Therapeutics For Cancer Tigit

Home Page: www.iteostherapeutics.com

ITOS Technical Analysis

321 Arsenal Street
Cambridge, MA 02472-5710
United States
Phone: 339 217 0161


Officers

Name Title
Dr. Michel Detheux Ph.D. Pres, CEO & Director
Mr. Matthew A. Call M.B.A. Chief Operating Officer
Dr. Joanne Jenkins-Lager M.D. Chief Medical Officer
Mr. Matthew Gall Chief Financial Officer
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer
Mr. Ryan Baker Head of Investor Relations
Mr. Phillipe Brantegem Vice-Pres of HR

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 12.5628
Trailing PE: 2.7686
Price-to-Book MRQ: 1.187
Price-to-Sales TTM: 1.6815
IPO Date: 2020-07-24
Fiscal Year End: December
Full Time Employees: 94
Back to stocks